Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

But maybe of more use are the hedges the company with $11 trillion in assets has articulated for a number of concerns that are currently weighing on investors' minds, according to strategists led by ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s ...

President-elect Donald Trump, speaking at his Mar-a-Lago estate Tuesday, said he would consider hitting Denmark with tariffs ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company’s business segments include, diabetes and ...